Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: "biochemical recurrence" Clear all

Conditions: Prostate Cancer
Interventions: Degarelix, Leuprolide; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: Male only
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 48
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more

Conditions: Prostate Adenocarcinoma
Interventions: Adaptive stereotactic body radiotherapy (SBRT); Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Localized Prostate Carcinoma
Interventions: Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy; Drug · Diagnostic Test · Procedure
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer
Interventions: bicalutamide, docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, flutamide, ketoconazole, paclitaxel, releasing hormone agonist therapy, vinblastine sulfate; Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 75
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 63 more

Conditions: Sickle Cell Disease
Interventions: Imatinib Mesylate; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Indianapolis, Indiana • Cincinnati, Ohio

Conditions: Prostate Cancer
Interventions: GnRH, Bicalutamide, Salvage radiation, Abiraterone, Prednisone, Apalutamide; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 95 Years · Male only
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 8
States / cities: San Diego, California • San Francisco, California • New Haven, Connecticut + 5 more

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: AAA617, ARPI: Abiraterone, ARPI: Enzalutamide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Casa Grande, Arizona • Gilbert, Arizona • Newport Beach, California + 2 more

Conditions: Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor
Interventions: PEG-interferon alfa-2b, bevacizumab, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Papillary Thyroid Cancer
Interventions: Selpercatinib, Sodium Iodine I-131, rhTSH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 3 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer, Cancer of the Prostate
Interventions: Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy; Device · Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostatic Neoplasm
Interventions: Fluciclovine PET/CT using a digital PET/CT; Diagnostic Test
Lead sponsor: University of Vermont; Other
Eligibility: 40 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Prostate Cancer
Interventions: Experimental beta probe, PSMA-PET; Other · Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Prostate Cancer
Interventions: docetaxel; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Brain Cancer
Interventions: Afatinib; Drug
Lead sponsor: Santosh Kesari; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Chronic Pancreatitis, Chronic Pain
Interventions: Quantitative Sensory Test 1, Quantitative Sensory Test 2, Quantitative Sensory Test 3; Diagnostic Test
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Colorectal Cancer
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Non ST Elevation Myocardial Infarction
Interventions: Eptifibatide, Placebo; Drug
Lead sponsor: Medical University of Silesia; Other
Eligibility: 21 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Biochemical Failure
Interventions: brassica intervention; Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 40 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Cancer Recurrent, Prostatic Cancer Metastatic
Interventions: Ga-68 PSMA-HBED-CC PET; Drug
Lead sponsor: Michael Graham PhD, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Prostate Cancer
Interventions: Testosterone Cypionate 100 MG/ML, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 40 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Post Acute Coronary Syndrome, Myocardial Ischemia
Interventions: Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Investigative Site, New Jersey

Conditions: Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
Interventions: Radiation Therapy Treatment Planning and Simulation, SBRT; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Male only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 3
States / cities: Rockford, Illinois • Johnson Creek, Wisconsin • Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: Radiation, Radiation SBRT only, ADT; Radiation · Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 46
States / cities: Antioch, California • Dublin, California • Fremont, California + 33 more

Search by objective public record fields.

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

SURPASS: Stereotactic Ultra-hypofractionated Radiotherapy for Post-prostatectomy Patients: Adaptive Salvage SBRT

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Imatinib for Pain in Sickle Cell Anemia

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Circulating Tumor DNA in High Risk Localized Prostate Cancer

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy

Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection and Evaluation of PSMA-PET for Diagnosis of Intraprostatic Lesions

Docetaxel in Treating Patients With Relapsed Prostate Cancer

Safety Study of Afatinib for Brain Cancer

Pancreatic Quantitative Sensory Testing (P-QST) to Predict Treatment Response for Pain in Chronic Pancreatitis

Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

Effects of Brassica or Indole-3-carbinol on Prostatectomy Patients With PSA Recurrence

68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment